Alnylam Pharmaceuticals (ALNY)
(Delayed Data from NSDQ)
$147.36 USD
+4.05 (2.83%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $147.46 +0.10 (0.07%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Brokerage Reports
Alnylam Pharmaceuticals, Inc. [ALNY]
Reports for Purchase
Showing records 321 - 340 ( 406 total )
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Conversation with Alnylam CEO Highlights Recent Advancements and Strong Forward Momentum
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Conversation with Alnylam CEO Highlights Recent Advancements and Strong Forward Momentum
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Completes Enrollment in Phase IIb Study of ALN-RSV01 for RSV Infection
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Completes Enrollment in Phase IIb Study of ALN-RSV01 for RSV Infection
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Pfizer Acquisition of Excaliard Pharmaceuticals Sets Rock-bottom Valuation for Regulus Therapeutics
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Pfizer Acquisition of Excaliard Pharmaceuticals Sets Rock-bottom Valuation for Regulus Therapeutics
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Demonstrates Compelling Human Proof of Concept Data for ALN-TTR01
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Demonstrates Compelling Human Proof of Concept Data for ALN-TTR01
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Grants InterfeRx Intellectual Property License for the Development of RNAi Therapeutics
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Grants InterfeRx Intellectual Property License for the Development of RNAi Therapeutics
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
REGN Phase II Results Validate Anti-PCSK9 as High Value Target for Treatment of Hypercholesterolemia
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
REGN Phase II Results Validate Anti-PCSK9 as High Value Target for Treatment of Hypercholesterolemia
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
New In Vivo Data for miR-21 Further Supports the Power of RegulusÂ’ microRNA Technology
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
New In Vivo Data for miR-21 Further Supports the Power of RegulusÂ’ microRNA Technology
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M